Kwazi Bethuel Gabuza
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kwazi Bethuel Gabuza has a total of 78 co-authors. Here are the top co-authors by number of shared publications:
- Rabia Johnson
Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, Cape Town 7505, South Africa
10 shared publications - Johan Louw
Biomedical Research and Innovation Platform (BRIP), South African Medical Research Council (SAMRC), Tygerberg 7505, South Africa
7 shared publications - Phiwayinkosi Vusi Dludla
Department of Biochemistry and Microbiology, University of Zululand, KwaDlangezwa 3886, South Africa
7 shared publications - Christo John Frederick Muller
Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg 7505, South Africa
5 shared publications - Elizabeth Joubert
Agricultural Research Council
5 shared publications - Lawrence Mabasa
Biomedical Research and Innovation Platform, South African Medical Research Council, Tygerberg, Cape Town 7505, South Africa
5 shared publications
Latest Publications
- Open Access
Signal-Amplification Strategies for Gold-Nanoparticle Lateral Flow Assays: A Structured Review of Limit-of-Detection Improvement Relative to Conventional GNP-LFA
Gold-nanoparticle lateral flow assays (GNP-LFAs) are widely used for point-of-care testing, but their colorimetric readout limits sensitivity. This exploratory structured review asked which signal-amplification strategies improve the limit of detection (LOD) relative to a conventional GNP-LFA, and by how much. Records came from a keyword-based, non-systematic search and were screened by one reviewer. Of 36 records assessed at full text, 29 were eligible and 26 gave a LOD ratio (51 comparator arms). Here, 19 studies (34 arms) used a gold label with a conventional comparator, and 8 (17 arms) used other labels or readouts and were summarised separately. Fold improvement ranged from no gain to about 1000-fold, and 11 of 51 arms gave less than 2-fold. Within a study, visual-limit ratios were equal to or up to about nine-fold larger than calibration-based ratios. Median gains were 162-fold for enzyme/catalytic amplification (four studies), 100-fold for physical pre-concentration (3 studies; 55-fold without the magnetic–plasmonic hybrid), 27-fold for silver/gold enhancement, and 24-fold for nanoparticle architecture. Flow control and test-zone pre-enrichment had a median of 1.4-fold (1.2-fold by calibration LOD alone; 6.3-fold by visual limit). Few studies per category, buffer-based comparisons, and non-independent arms limit these values, which do not rank mechanisms or establish clinical utility.
Open AccessSignal-Amplification Strategies for Gold-Nanoparticle Lateral Flow Assays: A Structured Review of Limit-of-Detection Improvement Relative to Conventional GNP-LFA
Gold-nanoparticle lateral flow assays (GNP-LFAs) are widely used for point-of-care testing, but their colorimetric readout limits sensitivity. This exploratory structured review asked which signal-amplification strategies improve the limit of detection (LOD) relative to a conventional GNP-LFA, and by how much. Records came from a keyword-based, non-systematic search and were screened by one reviewer. Of 36 records assessed at full text, 29 were eligible and 26 gave a LOD ratio (51 comparator arms). Here, 19 studies (34 arms) used a gold label with a conventional comparator, and 8 (17 arms) used other labels or readouts and were summarised separately. Fold improvement ranged from no gain to about 1000-fold, and 11 of 51 arms gave less than 2-fold. Within a study, visual-limit ratios were equal to or up to about nine-fold larger than calibration-based ratios. Median gains were 162-fold for enzyme/catalytic amplification (four studies), 100-fold for physical pre-concentration (3 studies; 55-fold without the magnetic–plasmonic hybrid), 27-fold for silver/gold enhancement, and 24-fold for nanoparticle architecture. Flow control and test-zone pre-enrichment had a median of 1.4-fold (1.2-fold by calibration LOD alone; 6.3-fold by visual limit). Few studies per category, buffer-based comparisons, and non-independent arms limit these values, which do not rank mechanisms or establish clinical utility.
- Open Access
- 9 October 2026
- Published by MDPI AG in Preprints.org
Signal-Amplification Strategies for Gold-Nanoparticle Lateral Flow Assays: A Structured Review of Limit-of-Detection Improvement Relative to Conventional GNP-LFA
Gold-nanoparticle lateral flow assays (GNP-LFAs) are attractive for point-of-care testing, but their conventional colorimetric readout often limits analytical sensitivity. This structured review asked which signal-amplification strategies produce the greatest improvement in limit of detection (LOD) relative to a conventional GNP-LFA comparator, and by what magnitude. Candidate records were identified through an investigator-directed keyword search and screened at full text by a single reviewer; 29 of 36 assessed records met eligibility, contributing 36 comparator arms across nine mechanism categories. Reported LOD fold-improvements ranged from no measurable gain to 1000x. Enzyme/catalytic (nanozyme) amplification spanned the widest range (4x–1000x across 5 arms), whereas silver/gold enhancement was the most frequently reported category (7 arms, 4 studies), with gains mostly below 40x and one study reporting up to 488x. Two arms showed no meaningful improvement over a conventional or visual-readout comparator. Gains varied substantially within and between categories and were analyte- and format-dependent; same-study and literature-baseline comparators answer different questions and should not be treated interchangeably. The largest gains came from mechanisms acting on detection chemistry rather than flow control or label loading, although most categories rest on few independent studies. Single-reviewer screening and an investigator-directed search are limitations.
- 9 October 2026
- Published by MDPI AG in Preprints.org
Open AccessSignal-Amplification Strategies for Gold-Nanoparticle Lateral Flow Assays: A Structured Review of Limit-of-Detection Improvement Relative to Conventional GNP-LFA
Gold-nanoparticle lateral flow assays (GNP-LFAs) are attractive for point-of-care testing, but their conventional colorimetric readout often limits analytical sensitivity. This structured review asked which signal-amplification strategies produce the greatest improvement in limit of detection (LOD) relative to a conventional GNP-LFA comparator, and by what magnitude. Candidate records were identified through an investigator-directed keyword search and screened at full text by a single reviewer; 29 of 36 assessed records met eligibility, contributing 36 comparator arms across nine mechanism categories. Reported LOD fold-improvements ranged from no measurable gain to 1000x. Enzyme/catalytic (nanozyme) amplification spanned the widest range (4x–1000x across 5 arms), whereas silver/gold enhancement was the most frequently reported category (7 arms, 4 studies), with gains mostly below 40x and one study reporting up to 488x. Two arms showed no meaningful improvement over a conventional or visual-readout comparator. Gains varied substantially within and between categories and were analyte- and format-dependent; same-study and literature-baseline comparators answer different questions and should not be treated interchangeably. The largest gains came from mechanisms acting on detection chemistry rather than flow control or label loading, although most categories rest on few independent studies. Single-reviewer screening and an investigator-directed search are limitations.
- Open Access
- 16 July 2026
- Published by LIDSEN Publishing Inc in Recent Progress in Materials
- Vol. 08  (03) , 1-17
Gold Nanoparticles-Based Colorimetric Assays Using Aptamers for Rapid Detection of Food- and Water-Borne Infections in Low-Income Countries
Food and water are essential resources for human survival; however, the increasing global population, urbanization, and climate change have placed a significant strain on their availability and safety, with major implications for public health and economic stability. Microbial contamination of food and water remains a critical global challenge, with bacteria responsible for more than 90% of foodborne illnesses. In the past decade, pathogens such as Salmonella, Campylobacter, and Listeria have been the leading causes of outbreaks. In contrast, diseases such as listeriosis and cholera constantly affect several African countries, with rapidly escalating infection rates. Early detection of pathogens in food and water is essential to prevent the spread of infections and reduce associated morbidity and mortality. Although current laboratory-based and on-site detection methods are highly sensitive and reliable, they are often limited by long assay times, labor-intensive procedures, and the need for specialized equipment and trained personnel. These limitations highlight the urgent need for rapid, cost-effective, and user-friendly diagnostic tools suitable for point-of-care (PoC) applications, particularly in resource-limited settings. While recent studies have explored nanomaterial-based detection strategies, existing reviews largely provide descriptive summaries and often lack a critical comparison of emerging biorecognition elements and their practical applicability in low-resource environments. This review provides a comprehensive and critical evaluation of aptamer-integrated gold nanoparticles (AuNPs)-based colorimetric assays, with a particular focus on lateral flow assays (LFAs) for the rapid detection of food- and water-borne pathogens. Key aspects, including assay performance, advantages and limitations of aptamer-based systems, and their potential for deployment in low-income countries (LICs) are discussed. By highlighting current advances, existing challenges, and future perspectives, this review aims to support the development of accessible and scalable diagnostic platforms for improving food and water safety.
- 16 July 2026
- Published by LIDSEN Publishing Inc in Recent Progress in Materials
- Vol. 08  (03) , 1-17
Open AccessGold Nanoparticles-Based Colorimetric Assays Using Aptamers for Rapid Detection of Food- and Water-Borne Infections in Low-Income Countries
Food and water are essential resources for human survival; however, the increasing global population, urbanization, and climate change have placed a significant strain on their availability and safety, with major implications for public health and economic stability. Microbial contamination of food and water remains a critical global challenge, with bacteria responsible for more than 90% of foodborne illnesses. In the past decade, pathogens such as Salmonella, Campylobacter, and Listeria have been the leading causes of outbreaks. In contrast, diseases such as listeriosis and cholera constantly affect several African countries, with rapidly escalating infection rates. Early detection of pathogens in food and water is essential to prevent the spread of infections and reduce associated morbidity and mortality. Although current laboratory-based and on-site detection methods are highly sensitive and reliable, they are often limited by long assay times, labor-intensive procedures, and the need for specialized equipment and trained personnel. These limitations highlight the urgent need for rapid, cost-effective, and user-friendly diagnostic tools suitable for point-of-care (PoC) applications, particularly in resource-limited settings. While recent studies have explored nanomaterial-based detection strategies, existing reviews largely provide descriptive summaries and often lack a critical comparison of emerging biorecognition elements and their practical applicability in low-resource environments. This review provides a comprehensive and critical evaluation of aptamer-integrated gold nanoparticles (AuNPs)-based colorimetric assays, with a particular focus on lateral flow assays (LFAs) for the rapid detection of food- and water-borne pathogens. Key aspects, including assay performance, advantages and limitations of aptamer-based systems, and their potential for deployment in low-income countries (LICs) are discussed. By highlighting current advances, existing challenges, and future perspectives, this review aims to support the development of accessible and scalable diagnostic platforms for improving food and water safety.
- Open Access
Maternal Methyl Donor Nutrients Modulate Developmental Genes in Mammary Tumors
Maternal nutrition during critical windows of development plays a pivotal role in shaping long-term disease susceptibility, including cancer risk. This study investigated whether maternal exposure to lipotropes (methyl donor nutrients) during pregnancy and lactation modulates gene expression in 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors in adult female offspring. Timed-pregnant Sprague-Dawley rats were fed with either a control or lipotrope-supplemented diet, with or without vitamin B6. Female offspring were exposed to DMBA at puberty, and mammary tumors were evaluated histologically and molecularly. DMBA-induced tumors displayed ductal carcinoma in situ-like morphology and significant upregulation of fetal mammary developmental genes (Tbx2 and Tbx3), the tumorigenesis-associated gene Tp53, and key epigenetic regulators (Hdac1, Dnmt1, and Mthfr). Estrogen receptor 1 (Esr1) mRNA expression also showed a significant increase. Maternal lipotropes supplementation significantly attenuated the expression of these genes in offspring tumors. Collectively, these findings demonstrate that maternal methyl donor nutrition modulates tumor-associated gene expression patterns, potentially by limiting the reactivation of developmental and epigenetic pathways in adulthood. This study highlights maternal nutrition as a modifiable early-life factor with important implications for long-term health programming.
Open AccessMaternal Methyl Donor Nutrients Modulate Developmental Genes in Mammary Tumors
Maternal nutrition during critical windows of development plays a pivotal role in shaping long-term disease susceptibility, including cancer risk. This study investigated whether maternal exposure to lipotropes (methyl donor nutrients) during pregnancy and lactation modulates gene expression in 7,12-dimethylbenzanthracene (DMBA)-induced mammary tumors in adult female offspring. Timed-pregnant Sprague-Dawley rats were fed with either a control or lipotrope-supplemented diet, with or without vitamin B6. Female offspring were exposed to DMBA at puberty, and mammary tumors were evaluated histologically and molecularly. DMBA-induced tumors displayed ductal carcinoma in situ-like morphology and significant upregulation of fetal mammary developmental genes (Tbx2 and Tbx3), the tumorigenesis-associated gene Tp53, and key epigenetic regulators (Hdac1, Dnmt1, and Mthfr). Estrogen receptor 1 (Esr1) mRNA expression also showed a significant increase. Maternal lipotropes supplementation significantly attenuated the expression of these genes in offspring tumors. Collectively, these findings demonstrate that maternal methyl donor nutrition modulates tumor-associated gene expression patterns, potentially by limiting the reactivation of developmental and epigenetic pathways in adulthood. This study highlights maternal nutrition as a modifiable early-life factor with important implications for long-term health programming.
- Open Access
Fetal Mammary Gland Development and Offspring’s Breast Cancer Risk in Adulthood
While advancements in early detection and improved access to care have significantly enhanced breast cancer survival rates, the disease remains a significant global malignancy, constituting approximately 12.5% of all new cancer cases and claiming nearly 700,000 lives in 2020. As a result, there is widespread consensus that the most sustainable solution lies in prevention. Indeed, preventive strategies, including lifestyle modifications and research into risk-reducing interventions, offer the potential to address the root causes of noncommunicable diseases such as breast cancer. While conventional wisdom has long attributed established risk factors for breast cancer to age, lifestyle, familial history, and reproductive factors, evidence highlights the maternal environment as a pivotal stage for fetal programming of disease risk, as elucidated in the developmental origins of health and disease (DOHaD) framework. Consequently, a growing body of research has been focused on elucidating epigenomic signatures that influence fetal development while shaping health outcomes and susceptibility to diseases later in life. This review aims to identify fetal mammary developmental genes that have been implicated in breast cancer etiology and the potential interplay of maternal environment in epigenetic programming of breast cancer risk in adulthood.
Open AccessFetal Mammary Gland Development and Offspring’s Breast Cancer Risk in Adulthood
While advancements in early detection and improved access to care have significantly enhanced breast cancer survival rates, the disease remains a significant global malignancy, constituting approximately 12.5% of all new cancer cases and claiming nearly 700,000 lives in 2020. As a result, there is widespread consensus that the most sustainable solution lies in prevention. Indeed, preventive strategies, including lifestyle modifications and research into risk-reducing interventions, offer the potential to address the root causes of noncommunicable diseases such as breast cancer. While conventional wisdom has long attributed established risk factors for breast cancer to age, lifestyle, familial history, and reproductive factors, evidence highlights the maternal environment as a pivotal stage for fetal programming of disease risk, as elucidated in the developmental origins of health and disease (DOHaD) framework. Consequently, a growing body of research has been focused on elucidating epigenomic signatures that influence fetal development while shaping health outcomes and susceptibility to diseases later in life. This review aims to identify fetal mammary developmental genes that have been implicated in breast cancer etiology and the potential interplay of maternal environment in epigenetic programming of breast cancer risk in adulthood.
- Open Access
- 21 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25  (11) , 5571
Phytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is a steatotic liver disease associated with metabolic syndrome (MetS), especially obesity, hypertension, diabetes, hyperlipidemia, and hypertriglyceridemia. MASLD in 43–44% of patients can progress to metabolic dysfunction-associated steatohepatitis (MASH), and 7–30% of these cases will progress to liver scarring (cirrhosis). To date, the mechanism of MASLD and its progression is not completely understood and there were no therapeutic strategies specifically tailored for MASLD/MASH until March 2024. The conventional antiobesity and antidiabetic pharmacological approaches used to reduce the progression of MASLD demonstrated favorable peripheral outcomes but insignificant effects on liver histology. Alternatively, phyto-synthesized metal-based nanoparticles (MNPs) are now being explored in the treatment of various liver diseases due to their unique bioactivities and reduced bystander effects. Although phytonanotherapy has not been explored in the clinical treatment of MASLD/MASH, MNPs such as gold NPs (AuNPs) and silver NPs (AgNPs) have been reported to improve metabolic processes by reducing blood glucose levels, body fat, and inflammation. Therefore, these actions suggest that MNPs can potentially be used in the treatment of MASLD/MASH and related metabolic diseases. Further studies are warranted to investigate the feasibility and efficacy of phytonanomedicine before clinical application.
- 21 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25  (11) , 5571
Open AccessPhytonanotherapy for the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as nonalcoholic fatty liver disease, is a steatotic liver disease associated with metabolic syndrome (MetS), especially obesity, hypertension, diabetes, hyperlipidemia, and hypertriglyceridemia. MASLD in 43–44% of patients can progress to metabolic dysfunction-associated steatohepatitis (MASH), and 7–30% of these cases will progress to liver scarring (cirrhosis). To date, the mechanism of MASLD and its progression is not completely understood and there were no therapeutic strategies specifically tailored for MASLD/MASH until March 2024. The conventional antiobesity and antidiabetic pharmacological approaches used to reduce the progression of MASLD demonstrated favorable peripheral outcomes but insignificant effects on liver histology. Alternatively, phyto-synthesized metal-based nanoparticles (MNPs) are now being explored in the treatment of various liver diseases due to their unique bioactivities and reduced bystander effects. Although phytonanotherapy has not been explored in the clinical treatment of MASLD/MASH, MNPs such as gold NPs (AuNPs) and silver NPs (AgNPs) have been reported to improve metabolic processes by reducing blood glucose levels, body fat, and inflammation. Therefore, these actions suggest that MNPs can potentially be used in the treatment of MASLD/MASH and related metabolic diseases. Further studies are warranted to investigate the feasibility and efficacy of phytonanomedicine before clinical application.
- Open Access
- 17 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19  (4) , e0297572
Afriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD
Background: Currently, it is acknowledged that vitamin E, insulin sensitizers and anti-diabetic drugs are used to manage non-alcoholic fatty liver disease (NAFLD), however, these therapeutic interventions harbour adverse side effects. Pioglitazone, an anti-diabetic drug, is currently the most effective therapy to manage NAFLD. The use of natural medicines is widely embraced due to the lack of evidence of their negative side effects. Rooibos has been previously shown to decrease inflammation and oxidative stress in experimental models of diabetes, however, this is yet to be explored in a setting of NAFLD. This study was aimed at investigating the effects of an aspalathin-rich green rooibos extract (Afriplex GRTTM) against markers of hepatic oxidative stress, inflammation and apoptosis in anin vitromodel of NAFLD.Methods: Oleic acid [1 mM] was used to induce hepatic steatosis in C3A liver cells. Thereafter, the therapeutic effect of Afriplex GRTTM, with or without pioglitazone, was determined by assessing its impact on cell viability, changes in mitochondrial membrane potential, intracellular lipid accumulation and the expression of genes and proteins (ChREBP,SREBF1,FASN,IRS1,SOD2, Caspase-3, GSTZ1, IRS1 and TNF-α) that are associated with the development of NAFLD.Results: Key findings showed that Afriplex GRTTMadded to the medium alone or combined with pioglitazone, could effectively block hepatic lipid accumulation without inducing cytotoxicity in C3A liver cells exposed oleic acid. This positive outcome was consistent with effective regulation of genes involved in insulin signaling, as well as carbohydrate and lipid metabolism (IRS1,SREBF1andChREBP). Interestingly, in addition to reducing protein levels of an inflammatory marker (TNF-α), the Afriplex GRTTMcould ameliorate oleic acid-induced hepatic steatotic damage by decreasing the protein expression of oxidative stress and apoptosis related markers such as GSTZ1 and caspase-3.Conclusion: Afriplex GRTTMreduced hepatic steatosis in oleic acid induced C3A liver cells by modulatingSREBF1,ChREBPandIRS-1gene expression. The extract may also play a role in alleviating inflammation by reducing TNF-α expression, suggesting that additional experiments are required for its development as a suitable therapeutic option against NAFLD. Importantly, further research is needed to explore its antioxidant role in this model.
- 17 April 2024
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 19  (4) , e0297572
Open AccessAfriplex GRTTM extract attenuates hepatic steatosis in an in vitro model of NAFLD
Background: Currently, it is acknowledged that vitamin E, insulin sensitizers and anti-diabetic drugs are used to manage non-alcoholic fatty liver disease (NAFLD), however, these therapeutic interventions harbour adverse side effects. Pioglitazone, an anti-diabetic drug, is currently the most effective therapy to manage NAFLD. The use of natural medicines is widely embraced due to the lack of evidence of their negative side effects. Rooibos has been previously shown to decrease inflammation and oxidative stress in experimental models of diabetes, however, this is yet to be explored in a setting of NAFLD. This study was aimed at investigating the effects of an aspalathin-rich green rooibos extract (Afriplex GRTTM) against markers of hepatic oxidative stress, inflammation and apoptosis in anin vitromodel of NAFLD.Methods: Oleic acid [1 mM] was used to induce hepatic steatosis in C3A liver cells. Thereafter, the therapeutic effect of Afriplex GRTTM, with or without pioglitazone, was determined by assessing its impact on cell viability, changes in mitochondrial membrane potential, intracellular lipid accumulation and the expression of genes and proteins (ChREBP,SREBF1,FASN,IRS1,SOD2, Caspase-3, GSTZ1, IRS1 and TNF-α) that are associated with the development of NAFLD.Results: Key findings showed that Afriplex GRTTMadded to the medium alone or combined with pioglitazone, could effectively block hepatic lipid accumulation without inducing cytotoxicity in C3A liver cells exposed oleic acid. This positive outcome was consistent with effective regulation of genes involved in insulin signaling, as well as carbohydrate and lipid metabolism (IRS1,SREBF1andChREBP). Interestingly, in addition to reducing protein levels of an inflammatory marker (TNF-α), the Afriplex GRTTMcould ameliorate oleic acid-induced hepatic steatotic damage by decreasing the protein expression of oxidative stress and apoptosis related markers such as GSTZ1 and caspase-3.Conclusion: Afriplex GRTTMreduced hepatic steatosis in oleic acid induced C3A liver cells by modulatingSREBF1,ChREBPandIRS-1gene expression. The extract may also play a role in alleviating inflammation by reducing TNF-α expression, suggesting that additional experiments are required for its development as a suitable therapeutic option against NAFLD. Importantly, further research is needed to explore its antioxidant role in this model.
- Open Access
- 20 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24  (20) , 15395
Doxorubicin-Induced Cardiomyopathy: A Preliminary Study on the Cardioprotective Benefits of 7-Hydroxyflavanone
The therapeutic properties of flavonoids are reported to offer cardioprotective benefits against doxorubicin (Dox)-induced cardiotoxicity (DIC). In the current study, we aimed to investigate the prophylactic properties of 7-hydroxyflavanone (7H), a flavonoid with antioxidative properties, against DIC. An in vitro model of DIC was established by exposing H9c2 cardiomyoblasts to Dox for 6 days. Similarly, cells were also co-treated with 7H to assess its ability to mitigate DIC. The data obtained indicate that 7H, as a co-treatment, alleviates Dox-induced oxidative stress by enhancing total glutathione content (p ≤ 0.001) and superoxide dismutase activity (p ≤ 0.001) whilst decreasing ROS (p ≤ 0.001), malondialdehyde production (p ≤ 0.001) and the secretion of interleukin-6 (p ≤ 0.001). The data also showed an improvement in mitochondrial function as shown via enhanced bioenergetics, mitochondrial membrane potential, and PGC1-alpha (p ≤ 0.05) and pAMPK (p ≤ 0.001) expression. The cardioprotective potential of 7H was further highlighted by its ability attenuate Dox-induced caspase 3/7 activity (p ≤ 0.001), apoptosis (p ≤ 0.001) and necrosis (p ≤ 0.05). In conclusion, our findings demonstrated the cardioprotective benefits of 7H and thus suggests that it could be a suitable candidate cardioprotective agent against DIC.
- 20 October 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24  (20) , 15395
Open AccessDoxorubicin-Induced Cardiomyopathy: A Preliminary Study on the Cardioprotective Benefits of 7-Hydroxyflavanone
The therapeutic properties of flavonoids are reported to offer cardioprotective benefits against doxorubicin (Dox)-induced cardiotoxicity (DIC). In the current study, we aimed to investigate the prophylactic properties of 7-hydroxyflavanone (7H), a flavonoid with antioxidative properties, against DIC. An in vitro model of DIC was established by exposing H9c2 cardiomyoblasts to Dox for 6 days. Similarly, cells were also co-treated with 7H to assess its ability to mitigate DIC. The data obtained indicate that 7H, as a co-treatment, alleviates Dox-induced oxidative stress by enhancing total glutathione content (p ≤ 0.001) and superoxide dismutase activity (p ≤ 0.001) whilst decreasing ROS (p ≤ 0.001), malondialdehyde production (p ≤ 0.001) and the secretion of interleukin-6 (p ≤ 0.001). The data also showed an improvement in mitochondrial function as shown via enhanced bioenergetics, mitochondrial membrane potential, and PGC1-alpha (p ≤ 0.05) and pAMPK (p ≤ 0.001) expression. The cardioprotective potential of 7H was further highlighted by its ability attenuate Dox-induced caspase 3/7 activity (p ≤ 0.001), apoptosis (p ≤ 0.001) and necrosis (p ≤ 0.05). In conclusion, our findings demonstrated the cardioprotective benefits of 7H and thus suggests that it could be a suitable candidate cardioprotective agent against DIC.
- Open Access
- 15 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24  (4) , 3868
Cyclopia intermedia (Honeybush) Induces Uncoupling Protein 1 and Peroxisome Proliferator-Activated Receptor Alpha Expression in Obese Diabetic Female db/db Mice
Previously, we reported that a crude polyphenol-enriched fraction of Cyclopia intermedia (CPEF), a plant consumed as the herbal tea, commonly known as honeybush, reduced lipid content in 3T3-L1 adipocytes and inhibited body weight gain in obese, diabetic female leptin receptor-deficient (db/db) mice. In the current study, the mechanisms underlying decreased body weight gain in db/db mice were further elucidated using western blot analysis and in silico approaches. CPEF induced uncoupling protein 1 (UCP1, 3.4-fold, p < 0.05) and peroxisome proliferator-activated receptor alpha (PPARα, 2.6-fold, p < 0.05) expression in brown adipose tissue. In the liver, CPEF induced PPARα expression (2.2-fold, p < 0.05), which was accompanied by a 31.9% decrease in fat droplets in Hematoxylin and Eosin (H&E)-stained liver sections (p < 0.001). Molecular docking analysis revealed that the CPEF compounds, hesperidin and neoponcirin, had the highest binding affinities for UCP1 and PPARα, respectively. This was validated with stabilising intermolecular interactions within the active sites of UCP1 and PPARα when complexed with these compounds. This study suggests that CPEF may exert its anti-obesity effects by promoting thermogenesis and fatty acid oxidation via inducing UCP1 and PPARα expression, and that hesperidin and neoponcirin may be responsible for these effects. Findings from this study could pave the way for designing target-specific anti-obesity therapeutics from C. intermedia.
- 15 February 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24  (4) , 3868
Open AccessCyclopia intermedia (Honeybush) Induces Uncoupling Protein 1 and Peroxisome Proliferator-Activated Receptor Alpha Expression in Obese Diabetic Female db/db Mice
Previously, we reported that a crude polyphenol-enriched fraction of Cyclopia intermedia (CPEF), a plant consumed as the herbal tea, commonly known as honeybush, reduced lipid content in 3T3-L1 adipocytes and inhibited body weight gain in obese, diabetic female leptin receptor-deficient (db/db) mice. In the current study, the mechanisms underlying decreased body weight gain in db/db mice were further elucidated using western blot analysis and in silico approaches. CPEF induced uncoupling protein 1 (UCP1, 3.4-fold, p < 0.05) and peroxisome proliferator-activated receptor alpha (PPARα, 2.6-fold, p < 0.05) expression in brown adipose tissue. In the liver, CPEF induced PPARα expression (2.2-fold, p < 0.05), which was accompanied by a 31.9% decrease in fat droplets in Hematoxylin and Eosin (H&E)-stained liver sections (p < 0.001). Molecular docking analysis revealed that the CPEF compounds, hesperidin and neoponcirin, had the highest binding affinities for UCP1 and PPARα, respectively. This was validated with stabilising intermolecular interactions within the active sites of UCP1 and PPARα when complexed with these compounds. This study suggests that CPEF may exert its anti-obesity effects by promoting thermogenesis and fatty acid oxidation via inducing UCP1 and PPARα expression, and that hesperidin and neoponcirin may be responsible for these effects. Findings from this study could pave the way for designing target-specific anti-obesity therapeutics from C. intermedia.
- Open Access
- 17 October 2022
- Published by Elsevier in Toxicology Reports
- Vol. 9, 1920-1928
In vitro and in vivo hepatotoxicity study of Afriplexâ„¢ GRT through an inflammatory response
- 17 October 2022
- Published by Elsevier in Toxicology Reports
- Vol. 9, 1920-1928
Open AccessIn vitro and in vivo hepatotoxicity study of Afriplexâ„¢ GRT through an inflammatory response